Donna Kato

President

RPI, A Division of Premier Research

Donna Kato, President, RPI, A Division of Premier Research, joined Premier Research in 2018 with the acquisition of RPI to further deepen Premier Research’s capabilities in Regulatory Affairs and Strategic Product Development Consulting. Bringing more than 30 years’ experience in the biotech and pharmaceuticals industry, Ms. Kato leads a team of professionals with deep preclinical, clinical and CMC expertise in the development of small molecules, biologics, cell-based therapies and combination products through all phases of development, including preparation of marketing applications and post approval activities.

Having helped hundreds of early stage resource constrained companies, the team’s strength lies in its collaborative, relationship-oriented approach, offering strategic and experience-based perspectives to facilitate productive interactions with regulatory authorities worldwide.

Ms. Kato started her career at Syntex in discovery research and later joined its worldwide regulatory affairs department (acquired by Roche) and has led regulatory affairs departments at several biotech start- ups. She holds a BS degree in biochemistry from the University of California, Davis and an MBA from Santa Clara University.

 

Senior Leadership

Ludo Reynders

Ludo Reynders

Chief Executive Officer
Krista Armstrong

Krista Armstrong

Senior Vice President, Clinical Development Services &, Global Head of Neuroscience
Mike Wilkinson

Mike Wilkinson

Chief Operations Officer
Dora Alvarado

Dora Alvarado

Vice President, Human Resources
Sean Russell

Sean Russell

Chief Commercial Officer
Charlie Nicholson

Charlie Nicholson

Chief Financial Officer
Tom Perkins

Tom Perkins

Senior Vice President, Corporate Development, & General Counsel
Colin Hayward

Colin Hayward

Chief Medical Officer